Esperance Pharmaceuticals Overview
- Year Founded
-
2005
- Status
-
Out of Business
- Employees
-
11
- Latest Deal Type
-
Out of Business
Esperance Pharmaceuticals General Information
Description
Operator of a biotechnology company intended to develop targeted anti-cancer drugs that selectively kill cancer cells without harming the normal cells. The company's drugs seek and destroy dividing and non-dividing cancer cells including cells known to be resistant to chemotherapeutics, enabling medical practitioners with drugs that kill cancer cells by a novel mechanism of action by disrupting their cell membranes leading to cell lysis.
Contact Information
Website
www.esperancepharma.comCorporate Office
- 909 Fannin Street
- Suite 2000
- Houston, TX 77010
- United States
Corporate Office
- 909 Fannin Street
- Suite 2000
- Houston, TX 77010
- United States
Esperance Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Out of Business | 19-Nov-2024 | Completed | Out of Business | |||
| 7. Secondary Transaction - Private | 01-Jul-2021 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC | 11-Jul-2019 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series C) | 30-Mar-2016 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series B) | 01-Jun-2011 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A1) | 09-Feb-2009 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 24-Nov-2008 | $3.2M | $12.2M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 18-Oct-2006 | $9M | $9M | Completed | Pre-Clinical Trials |
Esperance Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 9,000,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 9.02% |
Esperance Pharmaceuticals Patents
Esperance Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021195553-A1 | Lytic domain fusion constructs, checkpoint inhibitors, and methods of making and using same | Inactive | 26-Mar-2020 | ||
| AU-2013344701-A1 | Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same | Inactive | 15-Nov-2012 | ||
| CA-2910311-A1 | Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same | Inactive | 15-Nov-2012 | ||
| EP-2920212-A1 | Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same | Inactive | 15-Nov-2012 | ||
| EP-2920212-A4 | Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same | Inactive | 15-Nov-2012 | C07K14/59 |
Esperance Pharmaceuticals Signals
Esperance Pharmaceuticals FAQs
-
When was Esperance Pharmaceuticals founded?
Esperance Pharmaceuticals was founded in 2005.
-
Where is Esperance Pharmaceuticals headquartered?
Esperance Pharmaceuticals is headquartered in Houston, TX.
-
What is the size of Esperance Pharmaceuticals?
Esperance Pharmaceuticals has 11 total employees.
-
What industry is Esperance Pharmaceuticals in?
Esperance Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Esperance Pharmaceuticals a private or public company?
Esperance Pharmaceuticals is a Private company.
-
What is Esperance Pharmaceuticals’s current revenue?
The current revenue for Esperance Pharmaceuticals is .
-
How much funding has Esperance Pharmaceuticals raised over time?
Esperance Pharmaceuticals has raised $84.9M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process